DENVER, Oct. 25, 2016 -- Extraction Oil & Gas, Inc. (NASDAQ:XOG) will host a conference call on November 8, 2016 at 8 a.m. MDT (10 a.m. EDT) to discuss third-quarter 2016 financial and operating results. Earnings will be released after close of market on November 7, 2016. The full text of the release will be available on the company’s website at www.extractionog.com.
Those who would like to participate can dial into the number listed below approximately 15 minutes before the scheduled conference call time, and enter confirmation number 7606470 when prompted.
Third-Quarter 2016 Earnings Conference Call Information
| Date: | Tuesday, November 8, 2016 |
| Time: | 8:00 AM MDT / 10:00 AM EDT |
| Dial-In Number: | (844) 229-9561 (Domestic toll-free) |
| Conference ID: | 7606470 |
To access the audio webcast and related presentation materials, please visit the investor relations section of the company’s website at www.extractionog.com. A replay of the conference call will be available on the website for approximately 30 days following the call.
About Extraction Oil & Gas, Inc.
Denver-based Extraction Oil & Gas, Inc. (NASDAQ:XOG) is an independent energy exploration and development company focused on exploring, developing and producing oil and natural gas primarily in the Wattenberg Field in the Denver-Julesburg Basin of Colorado.
Investor Contact: Rusty Kelley, [email protected], 720-557-8302


Italy Fines Apple €98.6 Million Over App Store Dominance
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
FDA Approves Mitapivat for Anemia in Thalassemia Patients
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 



